Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Spero Therapeutics (SPRO) Accumulated Depreciation & Amortization (2016 - 2024)

Spero Therapeutics filings provide 9 years of Accumulated Depreciation & Amortization readings, the most recent being $3.6 million for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed 0.06% to $3.6 million in Q4 2024 year-over-year; TTM through Dec 2024 was $3.6 million, a 0.06% change, with the full-year FY2024 number at $3.6 million, changed 0.06% from a year prior.
  • Accumulated Depreciation & Amortization hit $3.6 million in Q4 2024 for Spero Therapeutics, roughly flat from $3.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.6 million in Q4 2024 to a low of $2.3 million in Q4 2020.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $3.3 million (2022), compared with a mean of $3.1 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 50.23% in 2020 and later rose 0.06% in 2024.
  • Spero Therapeutics' Accumulated Depreciation & Amortization stood at $2.3 million in 2020, then grew by 26.54% to $2.9 million in 2021, then rose by 12.92% to $3.3 million in 2022, then rose by 11.25% to $3.6 million in 2023, then increased by 0.06% to $3.6 million in 2024.
  • The last three reported values for Accumulated Depreciation & Amortization were $3.6 million (Q4 2024), $3.6 million (Q4 2023), and $3.3 million (Q4 2022) per Business Quant data.